Predominance of Beijing genotype in extensively drug resistant Mycobacterium tuberculosis isolates from a tertiary care hospital in New Delhi, India

International Journal of Mycobacteriology
Jyoti AroraVithal Prasad Myneedu

Abstract

Out of a total of 311 Mycobacterium tuberculosis isolates from sputum specimens subjected to first- and second-line drug-susceptibility testing (DST) at a hospital serving as a referral center for chronic tuberculosis (TB) cases in New Delhi, 232/311 (74.6%) isolates were found to be resistant to isoniazid and rifampicin. Among multidrug-resistant (MDR) isolates, 119/232 (51.3%) were resistant to four first-line drugs (streptomycin, isoniazid, rifampicin and ethambutol). Mono-resistance to isoniazid was observed in 18 (5.7%) isolates, while none of the isolates tested showed mono-resistance to rifampicin. 50/232 (21.5%) isolates met the definition of extensively drug resistant (XDR) TB, i.e., additional resistance to a fluoroquinolone and at least one of the three injectable second-line drugs: kanamycin, capreomycin, or amikacin. Spoligotyping of the XDR-TB isolates revealed 14 patterns; 39/50 (78%) isolates being grouped in three clusters vs. 11/50 (22%) isolates being unique. SIT1/Beijing represented the largest cluster (n=21, 42%), followed by SIT26/CAS1-Delhi (n=10, 20%) and SIT 53/T1 (n=8 isolates; 16%). This study corroborates recent observations from North India suggesting that both Beijing and CAS1-Delhi lineages consti...Continue Reading

References

Jul 27, 2002·Emerging Infectious Diseases·Judith R GlynnDick van Soolingen
Jun 23, 2004·Emerging Infectious Diseases·Urvashi Balbir SinghPradeep Seth
Mar 1, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Deepak AlmeidaAjita Mehta
Apr 20, 2006·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Naga SureshJitendra Nath Pande
Nov 1, 2006·Emerging Infectious Diseases·M Cristina GutierrezPhilip Supply
Dec 20, 2007·AIDS·Sarman SinghKrishnamoorthy Gopinath
May 26, 2009·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Jyoti AroraJitendra Nath Pande
Oct 16, 2009·Transactions of the Royal Society of Tropical Medicine and Hygiene·Nilanjan ChakrabortyShubhashish Kamal Guha
Jan 18, 2011·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Sankalp PurwarDevendra Singh Chauhan
Feb 24, 2011·Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery·Jaya Ruth AsirvathamGeeta Chacko
Mar 1, 2012·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Christophe DemayNalin Rastogi

❮ Previous
Next ❯

Citations

Feb 12, 2017·Journal of Epidemiology and Global Health·Jyoti AroraVithal Prasad Myneedu
Oct 17, 2019·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Husain PoonawalaSharon J Peacock
Aug 10, 2021·Frontiers in Public Health·Prince AsareDorothy Yeboah-Manu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.